Cerevel Therapeutics Holdings, (CERE) Financials

CERE Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 1.2 billion 569.6 million
2023-09-30 822.0 million 549.0 million
2023-06-30 894.4 million 543.9 million
2023-03-31 930.3 million 498.6 million

CERE Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -98.3 million 25.2 million
2023-09-30 -73.1 million 17.1 million
2023-06-30 -79.4 million 14.5 million
2023-03-31 -95.3 million 12.6 million

CERE Net Income

No data available :(

CERE Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 991.0 million - 31.2 million
2023-09-30 676.9 million - 28.7 million
2023-06-30 736.4 million - 29.5 million
2023-03-31 827.0 million 336.0 million 30.4 million

CERE Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 174.6 million
2023-09-30 157.5 million
2023-06-30 157.1 million
2023-03-31 156.6 million

CERE Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 902000 97.1 million 42.4 million 1.5 million
2023-09-30 513000 85.3 million 26.1 million -
2023-06-30 2.1 million 74.1 million 22.8 million -
2023-03-31 336000 78.2 million 21.4 million -

CERE Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 - 1.5 million
2023-09-30 - 1.4 million
2023-06-30 - 1.4 million
2023-03-31 - 1.3 million

CERE

Price: $42.55

52 week price:
19.59
43.59

Earnings Per Share: -2.67 USD

P/E Ratio: -17.17

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 300700

Market Capitalization: 7.6 billion

Links: